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 Radiotherapy (RT) is a part of the routine treatment of locally advanced or high-grade soft-tissue sarcomas (STS). However, 
RT has changed significantly over the last 20 years. Modern RT techniques have extended its potential application in STS 
treatment. That includes advances in contouring, fractionation regimens, RT techniques and combined treatment. This 
article summarizes the available data, current strategies and future research directions in RT for STS. 
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Introduction
Perioperative radiotherapy (RT) combined with wide local 
excision enables over 90% of local control in patients with 
localized soft tissue sarcomas (STS) of extremities or the 
trunk wall. According to the National Comprehensive Cancer 
Network (NCCN) and European Society for Medical Oncology 
(ESMO) guidelines, RT is recommended as a part of the routine 
treatment of locally advanced or high-grade STS, depending 
on clinicopathological factors such as tumor size, grade and 
its resectability [1, 2]. NCCN recommends perioperative RT in 
selected patients with stage I and in all stage II, III extremity, 
superficial trunk, or head/neck STS. Likewise, ESMO recom-
mends perioperative RT with wide excision in high-grade 
(G2–3), deep, large (>5 cm) STS. The role of RT in other clinical 
situations, such as superficial STS, high-grade <5 cm STS or 
low-grade >5 cm deep STS remains unclear; thus, the use of 
RT should be discussed at a multidisciplinary tumor board 
(MTB), given the risk of local recurrence, pathological diagnosis 
and potential toxicity. The issue of the treatment sequence is 
extensively discussed in literature. Currently, both neoadjuvant 
and adjuvant RT may be considered in localized STS, taking 
into account the risk of postoperative wound complications 
(tab. I) [3]. However, RT in STS has significantly changed over 
the last 20 years in many more aspects. 
Moreover, contemporary RT may play an important role 
in the management of patients with metastatic STS. Modern 
RT techniques, such as stereotactic body RT (SBRT), allows 
the delivery of a high dose to target volume with minimal 
involvement of surrounding healthy tissues. The use of mo-
tion-management techniques enable the irradiation of mo-
ving tumors, for example, lung metastases that are the most 
frequent metastatic site of STS. 
This article summarizes the available data, current strate-
gies and future research directions in RT for STS. That includes 
advances in contouring, fractionation regimens, RT techniques, 
and combined treatment. The scope of the article does not 
cover selected STS subtypes with separate guidelines, namely 
Ewing sarcoma, rhabdomyosarcoma, gastrointestinal stromal 
tumors and dermatofibrosarcoma protuberans. 
External beam radiotherapy
Contouring
Together with the evolution of RT techniques, RT planning 
in STS evolved from simple two-dimensions to complicated, 
volumetric shapes. Two-dimensional RT in STS required only 
the determination of field borders. Currently, a radiation 
oncologist delineates tumor volumes, elective margins and 
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the volumes of organs at risk. The contouring process varies 
depending on the treatment sequence. However, the main 
rule remains the same – the elective margin should follow 
the most probable path of local spread – namely areas of 
least resistance. In neoadjuvant RT, gross tumor volume (GTV) 
should be delineated on T1 contrast-enhanced magnetic 
resonance imaging (MRI) fusion with planning CT. The clinical 
target volume (CTV) should cover GTV, tumor-associated 
edema in T2 MRI and the elective margin of healthy tissues. 
In deeply-seated STS, it is recommended to add 1.5–2.0 cm 
to GTV radially and 4 cm longitudinally, stopping at anatomi-
cal barriers (for example bones, major vessels, fascias) [4]. In 
superficially-spreading STS, it is suggested to extend GTV by 
at least 4 cm in each direction, except the deep margin that 
should end at the nearest non-involved anatomical border. 
The delineation of organs at risk depends on the irradiated 
site, including large joints, skin, subcutaneous tissue and 
contralateral extremity. Due to the large volumes of primary 
tumors and extensive margins, the protection of organs at risk 
is challenging. However, the evidence from two clinical trials 
does not support a reduction of target volumes. In a phase III 
Randomised Trial of Volume of Post-operative Radiotherapy 
Given to Adult Patients With eXtremity Soft Tissue Sarcoma 
(VORTEX, NCT00423618), patients with STS were randomly 
assigned into postoperative RT with conventional and po-
stoperative RT with reduced margins (2 cm in each direction) 
[5]. The small number of events did not allow conclusions to 
be drawn regarding local relapse-free survival. Moreover, the 
authors found no difference between arms in limb function 
at 2 years. Thus, reduced margins cannot be recommended 
as a standard of care. Another phase II Radiation Therapy 
Oncology Group (RTOG) 0630 non-randomized single-arm 
clinical trial indicated that modern image-guided RT with 
simultaneous margin reduction enabled a low rate of late to-
xicity with good local control [6]. However, it was a single-arm 
clinical trial and it was not possible to conclude which factors 
(image-guided RT or margin reduction or both) contributed 
to the aforementioned results. Thus, conventional extensive 
margins remain a standard of STS contouring. 
Fractionation regimen
The recommended perioperative RT fractionation regimens 
for STS delivers 2.0 Gy per day, 5 times weekly, up to 50 Gy 
in preoperative radiotherapy and 60–66 Gy in postoperative 
radiotherapy [7]. In hypofractionated regimens, the total 
dose is divided into fewer fractions with an increased frac-
tion dose. Hypofractionated RT in STS has a radiobiological 
rationale. The alpha/beta ratio of STS seems to be lower 
than 10 Gy [8]. Thus, a higher dose per fraction should result 
in better tumor control. Furthermore, hypofractionated RT 
may allow for a reduction of the delivered total dose witho-
ut compromising tumor control. This may lead to healthy 
tissues being spared close to the target volume. Moreover, 
it can be combined with chemotherapy or targeted therapy 
[9]. Hypofractionated RT for STS was investigated in many 
prospective phase I or phase II clinical trials and prospective 
registries (tab. II); however there is no evidence from phase 
III trials to support its use in routine clinical practice [9–15]. 
Nevertheless, it may be used individually in selected patients 
upon the decision of the MTB.
Table I. Comparison of neoadjuvant and adjuvant radiotherapy in soft tissue sarcomas
Issue Adjuvant radiotherapy Neoadjuvant radiotherapy
delineation complicated (no GTV, fusion with preoperative imaging, 
postoperative changes)
easy (visible GTV)
target volume larger (tumor bed, scars, drainage, operative route, and 
margins)
smaller (GTV + margin)
healthy tissues move to the tumor bed pushed away by the tumor
dose higher (60–66 Gy EQD2) lower (45–50.4 Gy EQD2)
treatment time longer shorter
hypofractionation no/not known possible
pathological assessment unhindered hindered
tumor response none possible
resection margins no influence could improve
tumor seeding during resection no influence possible reduction
risk of early toxicity1 lower higher
risk of late toxicity1 higher lower
combination with chemotherapy possible possible
From Cancers (Basel). 2020 Aug; 12 (8): 2061. CC-BY 4.0. Copyright 2020 by Spałek et al.
1In conventionally fractionated radiotherapy. EQD2 – equivalent total dose in 2-Gy fractions; GTV – gross tumor volume
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Techniques
At the beginning of the 2000s, the vast majority of STS pa-
tients were irradiated with 2D and 3D-conformal RT that was 
reflected in the most important STS clinical trials [16–18]. Ra-
diation oncologists who are experienced in STS slowly adapted 
modern highly-conformal RT techniques. This was caused by 
the risk of delivery of small doses to high volumes of healthy 
tissues, including the whole extremity circumference
Theoretically, that may translate into a high occurrence of 
significant late toxicities. However, the results of two clinical 
trials do not confirm this hypothesis. In the RTOG-0630 trial, 
the authors found a significant reduction of late toxicities in 
patients with extremity STS who had been treated with pre-
operative image-guided highly conformal RT with reduced 
margins when compared with the results of the CAN-NCIC-
-SR2 trial with 3D-conformal RT [6, 17]. In another phase II 
clinical trial, O’Sullivan et al. investigated the use of intensi-
ty-modulated RT (IMRT) in reducing wound complications 
after preoperative RT for lower extremity STS [19]. IMRT was 
used to protect healthy tissues (skin flaps for wound closure, 
bone, or other uninvolved soft tissues). The incidence of 
wound complications in the investigated group irradiated 
with IMRT was lower (30.5%) than in the aforementioned 
CAN-NCIC-SR2 trial (43%). However, this difference was not 
statistically significant. Additionally, preoperative RT signifi-
cantly decreased the need for tissue transfer. Due to the high 
probability of tumor volume size changes during preoperati-
ve RT, an image-guided approach is recommended [20]. An 
Table II. Preoperative hypofractionated radiotherapy regimens in soft tissue sarcomas in major published studies
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Adapted from Front Oncol. 2020 Jun 5; 10: 993. CC-BY 4.0. Copyright 2020 by Spałek and Rutkowski
AI – doxorubicin, ifosfamide; EI – epirubicin, ifosfamide; CHT – chemotherapy; CT – clinical trial; DM – distant metastases; DRFS – distant recurrence-free survival; JS – joint stiffness; 
MLPS – myxoid liposarcomas; ND – no data; OS – overall survival; PFS – progression-free survival; RT – radiotherapy; STS – soft tissue sarcomas; * – various regimens were used; 
& – only part of a group received chemotherapy 
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assumed that the RBE of protons is 1.1, whereas in carbon 
ions RBE equals 2.5-3. PT was used to irradiate sarcomas of 
the base of the skull and spine. It could be also considered 
in selected patients with extremity STS [22]. The vast majority 
of data concerning PT in STS, describes its efficacy in rhab-
domyosarcomas and Ewing sarcomas [23]. One study was 
conducted to assess the effectiveness and safety of PT for 
unresectable or incomplete resected bone sarcomas and STS 
of the pelvis [24]. 91 patients, mostly with a primary tumor 
(90%) were treated with proton and carbon ion therapy. Re-
sults showed 83% of them with 3-year overall survival, 72% 
with 3-year progression-free survival, and 92% with 3-year 
local control. All patients completed therapy; however, acute 
grade ≥3 toxicities were observed in 22 patients (24%). Late 
grade ≥3 toxicities were observed in 23 patients (25%). Ano-
ther study of 128 patients with unresectable localized axial 
STS, treated with carbon ion therapy, showed 65% 5-year 
local control and 49% 5-year overall survival [25]. Yang et al 
used carbon ion RT to treat patients with locally recurrent 
or radiation-induced second primary STS of the head and 
neck [26]. Among the 19 patients, 1-year local control and 
1-year overall survival reached 75% and 87%, respectively. 
A Japanese group conducted a phase I/II trial that aimed to 
determine the effectiveness of carbon ion therapy for loca-
lized primary sarcomas of the extremities [27]. Nine patients 
had primary diseases and eight had recurrent diseases. In 
65% of patients, a radiological response was observed. The 
5-year overall survival and 5-year local control was 56% and 
76%, respectively. Local recurrences were observed in four 
patients, three died due to systemic diseases and one was 
salvaged by repeated carbon ion RT. The aforementioned 
results indicate the good local efficacy and tolerance of PT 
in STS. However, further research on that topic is required to 
establish clear indications for PT in STS.
Brachytherapy
The effectiveness of interstitial brachytherapy in STS has been 
confirmed in several studies. Brachytherapy in STS is usually 
applied intraoperatively or postoperatively. Either sole brachy-
therapy or as a boost after external beam RT were investigated 
[28–31]. In selected clinical situations, brachytherapy may be 
superior to external beam RT due to the reduction of treatment 
time, higher dose intensity and better sparing of surrounding 
healthy tissues. However, brachytherapy and external beam 
RT were not directly compared in any prospective  study. 
Moreover, the majority of available data describe the use of 
low dose rate brachytherapy whereas data regarding high 
dose rate brachytherapy are limited [32–35]. The American 
Brachytherapy Society summarized the available evidence on 
brachytherapy in STS and published a consensus statement 
regarding indications, techniques, implantation, fractionation 
regimens and special considerations [36]. Importantly, it is 
suggested that brachytherapy as monotherapy can be consi-
interesting option for reducing the risk of errors could be the 
introduction of adaptive RT [21].
Other RT techniques
Stereotactic body radiotherapy
Modern diagnostic tools and the growing number of available 
options for effective systemic treatment introduced the terms 
oligometastatic and oligoprogressive disease in STS patients. 
For many years, surgery remained the only curative modality in 
the case of isolated countable metastases, mostly to the lungs. 
Existing data suggest an improvement in  overall survival after 
the resection of a limited number of metastases in STS patients. 
The development of dynamic RT techniques with motion-ma-
nagement enabled precise treatment of small volumes with 
high-dose radiation accompanied by concomitant sparing of 
the surrounding healthy tissues. Thus, SBRT could be offered to 
patients who are not suitable candidates or refuse surgery. This 
kind of treatment may provide high local control with short 
overall treatment time and a good toxicity profile. A Swedish 
group analyzed the outcomes of 46 patients with 136 distant 
STS metastases treated with SBRT between 1994 and 2005 
using a 3D-conformal multifield RT and a stereotactic body-
-frame. The majority of treated lesions were lung metastases. 
The authors described an excellent overall response rate that 
reached almost 90% with acceptable treatment tolerance; 
only two serious non-lethal adverse events were observed. In 
a recently designed prospective phase III international rando-
mized clinical trial (Stereotactic Body Radiotherapy in Patients 
With Rare Oligometastatic Cancers, OligoRARE, NCT04498767), 
the authors aim to investigate the effect of adding SBRT to the 
standard of care treatment on overall survival in patients with 
rare oligometastatic cancers, including STS. SBRT will be given 
to all metastatic sites as an additional modality to the current 
standard of care. Patients will be randomly allocated to one of 
two arms: standard of care or standard of care with SBRT to all 
metastatic lesions. Full results will be available within 10 years. 
Particle therapy
Particle therapy (PT), such as proton and carbon ion therapy, 
has several potential advantages compared to conventional 
photon based therapy, which, due to the Bragg curve, can 
provide better dose distribution. Based on these unique 
features, PT may allow escalation of the dose to the tumor 
while reducing the dose to the surrounding organs at risk. 
Moreover, charged particles, such as carbon ions, deposit 
the radiation dose in a way that causes complex DNA da-
mage at multiple sites which is challenging for a single DNA 
damage response pathway to repair; this makes their usage 
in RT potentially effective in the management of radio- and 
chemo-resistant tumors like STS. The dose of PT is measured 
in Gray-equivalents, calculated as a carbon physical dose in 
Gy, multiplied by relative biological effectiveness (RBE). It is 
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dered in low-risk STS or in situations of re-irradiation whereas 
a brachytherapy boost may be applied in high-risk STS or in 
cases of larger target volumes.  
Hyperthermia
Hyperthermia is a cancer treatment in which a heated volume 
is exposed to temperatures between 41–43°C. It works through 
the application of electromagnetic energy for a defined period 
of time. Heat can be delivered using an electromagnetic field, 
ultrasound or perfusion method. Hyperthermia in oncology 
comprises three subgroups: whole body hyperthermia, re-
gional hyperthermia and local hyperthermia. It is widely used 
in combination with RT or chemotherapy in various cancers, 
including STS. The effectiveness of hyperthermia combined 
with chemotherapy in locally advanced STS was confirmed 
in a phase III randomized clinical trial [37, 38]. However, there 
is no such data on the combination of hyperthermia with 
radiotherapy in STS. Currently, the Polish Sarcoma Group con-
ducts a prospective phase II clinical trial with neoadjuvant 
hyperthermia with radiotherapy (3.25 Gy to 32.5 Gy, SINDIR, 
NCT03989596) in patients with locally advanced STS. Moreover, 
a combination of RT with hyperthermia may be offered to 
patients with radiation-induced or in-field recurrent STS. De 
Jong et al. retrospectively assessed a cohort of patients who 
received RT with hyperthermia as a treatment for STS which 
grew in previously irradiated volumes within the thoracic re-
gion [39]. Two hypofractionated regimens with hyperthermia 
twice a week were used (3 Gy to 36 Gy; or 4 Gy to 32 Gy). 
Thirteen patients underwent treatment with curative intent. 
The remaining three patients received RT with hyperthermia 
postoperatively. In seven patients the complete response was 
observed, whereas partial response was found in two patients. 
Despite the previous irradiation, both early and late toxicities 
were acceptable. The authors described only one severe late 
toxicity, namely arm ischemia that required limb amputation, 
occurring several years after treatment. Nevertheless, no pro-
spective evidence on RT with hyperthermia in this clinical 
situation exists. Recently, the Polish Sarcoma Group started a 
phase II clinical trial with hyperthermia combined with hypo-
fractionated RT in radiation-induced or in-field recurrent STS 
(HOT, NCT04398095).
Tailored radiotherapy
STS are very heterogeneous and present a wide spectrum of 
radiosensitivity. Some STS subtypes are considered to be espe-
cially radiosensitive compared with other STS. In a prospective 
phase II single arm clinical trial conducted by the Polish Sarco-
ma Group, patients with locally advanced myxoid liposarcomas 
received one-week RT (25 Gy in five fractions) followed by a 6–8 
weeks gap before surgery [12]. 29 patients were enrolled on 
the trial. The investigated method did not increase the wound 
complication rate (37.9%) compared to other STS trials, where-
as in all analyzed surgical specimens a significant response to 
RT was observed. An interesting approach could be the imple-
mentation of radiogenomics models in predicting response to 
the radiation of selected STS. A research group from the H. Lee 
Moffitt Cancer Center and Research Institute (Tampa, Florida, 
USA) and the Netherlands Cancer Institute (Amsterdam, the 
Netherlands) developed and validated a robust multigene 
expression model of intrinsic tumor radiosensitivity [40]. To 
predict the response to treatment, scientists created a model 
of radiosensitivity as a function of gene expression and other 
factors in a form of a rank-based linear regression algorithm 
to establish the radiosensitivity index (RSI). This model was 
used in further research to calculate the RSI of 113 resected 
STS samples [41]. The study investigated a predictive value of 
RSI for locoregional control with preoperative RT in STS. The 
whole group was divided into two cohorts based on RSI, ra-
diosensitive and radioresistant STS. The four-year locoregional 
control was better in the radiosensitive STS cohort than in the 
cohort of the radioresistant tumor (95% vs. 79.3%, p = 0.021). 
The genomic-adjusted RT may be an important direction for 
further research in STS radiation oncology.
Nanoparticles
Using agents to radiosensitize tumor cells has been tested for 
many years. A multicenter, randomized, II/III phase clinical trial 
aimed at investigating the efficacy of hafnium oxide nanopar-
ticles (NBTXR3) as a local radiosensitizer added to neoadjuvant 
RT. Patients with locally advanced resectable STS of extremities 
or the trunk wall, requiring preoperative RT, were enrolled. 
The control group received preoperative RT (2 Gy to 50 Gy) 
alone, whereas the study group received a single intratumoral 
administration of NBTXR3 before preoperative RT. The primary 
endpoint was the proportion of patients with a complete pa-
thological response. Analysis of 176 patients – 87 in the study 
group and 89 in the control group – showed a  statistically 
significant difference in the pathological complete response 
between the study group (14 patients) and the control group 
(7 patients) (p = 0.044). R0 resection  was achieved more fre-
quently in the NBTXR3 group compared to the RT alone group 
(p = 0.042). Serious adverse events occurred in 39% of patients 
in the NBTXR3 group and 30% of patients in the RT alone group. 
In both groups, the postoperative wound complication was 
according to Common Terminology Criteria for Adverse Events 
v 4.0. The most common grade ≥3 adverse event related to 
NBTXR3 injection was pain (4%) and hypotension (7%). The 
administration of NBTXR3 does not increase RT-related toxici-
ties. The most common grade ≥3 adverse event related to RT 
was skin injuries in both groups: 6% in the NBTXR3 group and 
4% in the RT alone group. An NBTXR3 injection before neo-
adjuvant RT may be a promising radioenhancer that improves 
the effectiveness of locally advanced STS treatment with no 
increase in RT-related toxicities. However, there are no long-
-term results, therefore the late toxicity profile and efficacy of 
nanoparticles with RT in STS are still unknown.
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Spatially-fractionated radiotherapy
In some STS, the utilization of RT is greatly limited by the bulky 
size and tolerance of surrounding healthy tissue. Advances in 
RT has led to the development of special techniques of treating 
bulky tumors. One of them is spatially fractionated radiation 
therapy applied through sieve-like collimators, namely GRID 
therapy [42]. A modern adaptation of GRID, 3D-lattice RT, uses 
highly conformal RT techniques to emulate grid-like patterns 
within the tumor volume [43]. The aforementioned techniques 
showed promising results in the treatment of large abdomi-
nal gynecological tumors [44, 45]. In the analysis performed 
at the University of Kentucky (Lexington, Kentucky, USA), 37 
patients with locally advanced STS were treated with single 
fraction 3D-lattice RT (12–20 Gy) before standard conventio-
nally-fractionated RT (1.8–2 Gy to 50–60 Gy) or moderately 
hypofractionated RT (2.25–3 Gy to 30–40 Gy) [46]. The average 
tumor size was 14x14 cm. Among those patients who under-
went surgery (15/37), a complete pathological response was 
observed in seven patients (47%), whereas a partial response 
was seen in eight patients (53%). Among those 15 patients, 
two experienced grade 3 skin toxicity and three presented 
delayed wound healing. The median survival of patients who 
underwent surgery was 18.6 months with a low local failure 
rate (20%) and high occurrence of distant metastases (74%). 
Among patients without surgery, two presented a complete 
clinical response, ten had a partial response, five showed stable 
disease and five were not evaluable. In another study with 
spatially-fractionated RT, 14 patients with bulky STS received 
a single dose of 18 Gy followed by conventionally fractionated 
RT (2 Gy to 50 Gy) with concomitant ifosfamide-based che-
motherapy [47]. They were subsequently referred to surgery. 
Twenty patients completed the whole protocol; treatment 
was prematurely stopped for one patient due to grade 3 skin 
toxicity. One patient underwent a foot amputation, the others 
underwent limb-sparing surgery. In 12/13 patients, negative 
margins were achieved. Two patients experienced delayed 
wound healing. Interestingly, in 9/14 patients >90% tumor ne-
crosis in surgical specimens was present. No local recurrences 
were observed. To summarize, spatially-fractionated RT may be 
a valuable treatment option of locally advanced STS; however, 
prospective trials are awaited. 
Retroperitoneal soft tissue sarcomas 
Particular attention should be paid to retroperitoneal STS. 
Perioperative RT is a part of routine treatment in extremity or 
trunk wall STS, whereas its role in retroperitoneal STS rema-
ins uncertain. The main limitations are large target volumes 
and their localization within the abdominal cavity, close to at 
risk radiosensitive organs. In recently published results from 
a phase III randomized study of preoperative radiotherapy plus 
surgery versus surgery alone for patients with retroperitoneal 
STS (STRASS, EORTC 62092), the addition of preoperative RT to 
surgery did not improve the abdominal relapse-free survival 
[48]. Moreover, a large retrospective study performed by the 
Trans-Atlantic Retroperitoneal Sarcoma Working Group, sho-
wed multivariate analysis indicated no benefit in local control 
of perioperative RT in retroperitoneal STS [49]. In turn, another 
study presented prolonged local recurrence-free survival in 
patients with retroperitoneal STS who received preoperative 
RT [50]. Additionally, the Surveillance, Epidemiology, and End 
Results analysis showed a benefit to overall survival by adding 
adjuvant RT after resection of high-grade retroperitoneal STS 
[51]. To sum up, the current evidence does not support the 
routine use of perioperative RT in patients with retroperitoneal 
STS; however, it could be used in selected patients depending 
on the decision of the MTB. The role of RT in the management 
of residual or recurrent retroperitoneal STS is unknown. Con-
temporary RT techniques, such as MR-based RT or particle the-
rapy, may open up new possibilities for this group of patients.
Summary
Multiple innovations in RT have been introduced over the 
last 20 years. The vast majority of them are used to improve 
the results of multidisciplinary treatment of STS. This includes 
advances in external beam RT as well as more widespread use 
of existing experimental methods and the introduction of new 
approaches. Further evaluation of new strategies is warranted, 
but a part of them could be currently used in selected STS 
patients depending on the decision of the MTB.
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